InsidersTradesSigma
Track the Jasper Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Jasper Therapeutics, Inc. has published 36 insider filings. Market capitalisation: €29.4m. The latest transaction was disclosed on 24 September 2025 (Acquisition). Among the most active insiders: Mahal Jeetinder Singh. All data is accessible without an account.
36
Insider Decl.
n/a
Thresholds
€15m
11 ops.
Buy Volume
€216,854
6 ops.
Sell Volume
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 September 2025
Declarations36 total
41,000 shares@ US$2.4383.0% of flowVoting Common StockSEC:0001213900-25-091105:0
Canonical exit: 21 Dec 2025 (T+90)
20,000 shares@ US$2.43100.0% of flowVoting Common StockSEC:0001213900-25-091104:0
Canonical exit: 21 Dec 2025 (T+90)
41,000 shares@ US$2.4331.1% of flowVoting Common StockSEC:0001213900-25-091099:0
Canonical exit: 21 Dec 2025 (T+90)
41,000 shares@ US$2.43100.0% of flowVoting Common StockSEC:0001213900-25-091096:0
Canonical exit: 21 Dec 2025 (T+90)
900 shares@ US$7.105.6% of flowVoting Common StockSEC:0001213900-24-108551:0
900 shares@ US$7.105.3% of flowVoting Common StockSEC:0001213900-24-078214:0
900 shares@ US$7.105.4% of flowVoting Common StockSEC:0001213900-24-052215:0
400 shares@ US$4.1735100.0% of flowVoting Common StockSEC:0001213900-24-051417:0
900 shares@ US$7.105.4% of flowVoting Common StockSEC:0001213900-24-021961:0
190,000 shares@ US$12.9534.6% of flowVoting Common StockSEC:0000950170-24-014017:0
Canonical exit: 8 May 2024 (T+90)
350,000 shares@ US$12.95100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0000921895-24-000337:0
Canonical exit: 8 May 2024 (T+90)
10,000 shares@ US$0.648634.3% of flowVoting Common StockSEC:0001213900-23-091458:0
Canonical exit: 26 Feb 2024 (T+90)
10,000 shares@ US$0.638333.8% of flowVoting Common StockSEC:0001213900-23-089579:0
Canonical exit: 19 Feb 2024 (T+90)
10,000 shares@ US$0.596531.9% of flowVoting Common StockSEC:0001213900-23-088896:0
Canonical exit: 14 Feb 2024 (T+90)
87,531 shares@ US$0.8537.8% of flowVoting Common StockSEC:0001013762-23-003902:0
37,126 shares@ US$0.8527.5% of flowVoting Common StockSEC:0001013762-23-003903:0
7,965 shares@ US$0.85089.9% of flowVoting Common StockSEC:0001013762-23-003901:0
9,000 shares@ US$0.715.4% of flowVoting Common StockSEC:0001213900-23-048683:0
8,500 shares@ US$1.4417.0% of flowVoting Common StockSEC:0001213900-23-029888:0
7,000 shares@ US$1.48100.0% of flowVoting Common StockSEC:0001213900-23-029901:0
9,075 shares@ US$1.4903100.0% of flowVoting Common StockSEC:0001213900-23-029900:0
37,126 shares@ US$1.4645.3% of flowVoting Common StockSEC:0001213900-23-029893:0
87,531 shares@ US$1.4662.2% of flowVoting Common StockSEC:0001213900-23-029896:0
2,666,666 shares@ US$1.50100.0% of flowVoting Common StockSEC:0001209191-23-024058:0
Canonical exit: 27 Apr 2023 (T+90)
3,133,333 shares@ US$1.5065.4% of flowVoting Common StockSEC:0000899243-23-003059:0
Canonical exit: 27 Apr 2023 (T+90)
25 of 36 declarations
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for hematological diseases. It employs cell biology-based approaches to enhance patient treatments.